Preclinical evaluation of PARP inhibition as a treatment for endometrioid endometrial carcinomas. Background: Increased vascular permeability greatly enhances liposome deposition in tumors.
Monthly intravenous pegylated liposomal doxorubicin (PLD) 50 mg m −2, although well tolerated, showed almost no activity in this phase II study of 16 patients with advanced hepatocellular carcinoma ...
PROLOGIS ($PLD) posted quarterly earnings results on Wednesday, April 16th. The company reported earnings of $1.42 per share, beating estimates of $0.61 by $0.81. The ...
Phospholipase D (PLD) is an essential enzyme responsible for the production of the lipid second messenger phosphatidic acid. Phosphatidic acid participates in both G protein–coupled receptor and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback